Virginia Savova
Research Subjects
Research Interests
Virginia Savova has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
Emanuele de Rinaldis
Precision Medicine and Computational Biology, Sanofi US, Cambridge, MA, United States
11 shared publicationsMathew Chamberlain
Sanofi, 270 Albany St, Cambridge, MA 02139, USA
6 shared publications- Nima Nouri
Precision Medicine Computational Biology, Sanofi , Cambridge, MA 02141
5 shared publications Richa Hanamsagar
Sanofi, 270 Albany St, Cambridge, MA 02139, USA
5 shared publications- Emanuele de Rinaldis
Sanofi, Cambridge, MA, USA
4 shared publications Giorgio Gaglia
Precision Medicine and Computational Biology, Sanofi, 350 Water Street, Cambridge, MA 02141, USA
4 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Springer Nature in Research Square
Bevacizumab-associated mesenchymal expansion in paediatric high-grade glioma is accompanied by intercellular VEGFA – AXL coupling
While anti-VEGF therapy is hypothesised to induce mesenchymal transition in high-grade glioma via hypoxia and myeloid remodelling, this dynamic remains unresolved at the resolution of defined malignant cell states in paediatric disease. Here, we reanalysed a longitudinal paediatric high-grade glioma single-nucleus atlas (Sussman et al., 2026; 401,253 cells, 16 patients, 32 samples) integrated with per-patient treatment histories. Applying multiple independent trajectory methods—including potency ordering, expression entropy, root-free Markov kernels, and optimal transport—we identified robust associations among malignant states. Although the original atlas grouped Transition 1 and Transition 2 as equivalent intermediate states between the astrocytic/mesenchymal and proneural programmes, our analyses reveal them as distinct entities with near-disjoint fate profiles and opposing positions across all lateness orderings. This confirms, via independent methods, a separation previously implied by motif-accessibility and ligand-receptor analyses. Crucially, Transition 2 represents a transcriptionally active state adjacent to the mesenchymal-like (MES-like) phenotype, accounting for 32.3% of MES-like nearest neighbours (a 2.9-fold enrichment over background). While initial reports noted no significant post-therapy shifts in overall malignant state composition, we found that the MES-like state contracts in bevacizumab-naive patients but expands under bevacizumab exposure, with the steepest increases observed following bevacizumab combined with checkpoint inhibition (0.07 to 0.372; patient-level permutation p = 0.027 for deltas, p = 0.003 for late-stage values). Concurrently, the myeloid compartment shifts toward a bone-marrow-derived macrophage (BMDM) phenotype. We demonstrate that BMDM polarisation strongly correlates with MES-like cellular proportions across samples (ρ = +0.83). This relationship remains robust after controlling for ambient RNA contamination, cell abundance, and leave-one-patient-out analyses, and persists after adjusting for hypoxia scores calculated outside the mesenchymal compartment (partial ρ = +0.64, p = 0.0008). Restricting our analysis to seven post-treatment samples from six bevacizumab-exposed patients revealed a striking cross-compartment coupling between myeloid VEGFA and malignant AXL (r = + 0.998 overall; r = + 0.946 specifically against AXL in MES-like cells). Within the malignant compartment, expression peaks in distinct states—AXL in Transition 2 (z = + 0.189) and VEGFA in the MES-like state (z = + 0.702). This intercellular interaction is arm-specific, invariant to leave-one-patient-out omission, resides at the 100th percentile of an empirical null distribution (n = 3,540 pairs), and withstands rigorous adjustment for hypoxia, cellular composition, sequencing depth, and primary technical or biological axes. This coupling is independent of canonical VEGF signalling: receptors VEGFR1, VEGFR2, and VEGFR3 are detectable in fewer than 1% to 8% of cells across both compartments, and tested candidate messengers fail to account for the axis. Neuropilins emerge as the sole abundant VEGFA-binding molecules (NRP1 expressed in 30% to 46% of cells). NRP1 is upregulated in bevacizumab-exposed tumours beyond compositional expectations and represents a cognate receptor spared by bevacizumab blockade. Finally, a malignant IL34-driven myeloid recruitment axis is evident in bevacizumab-treated tumours, though it remains perfectly collinear with concurrent checkpoint inhibition.
- 1 October 2026
- Published by Springer Nature in Research Square
Open AccessBevacizumab-associated mesenchymal expansion in paediatric high-grade glioma is accompanied by intercellular VEGFA – AXL coupling
While anti-VEGF therapy is hypothesised to induce mesenchymal transition in high-grade glioma via hypoxia and myeloid remodelling, this dynamic remains unresolved at the resolution of defined malignant cell states in paediatric disease. Here, we reanalysed a longitudinal paediatric high-grade glioma single-nucleus atlas (Sussman et al., 2026; 401,253 cells, 16 patients, 32 samples) integrated with per-patient treatment histories. Applying multiple independent trajectory methods—including potency ordering, expression entropy, root-free Markov kernels, and optimal transport—we identified robust associations among malignant states. Although the original atlas grouped Transition 1 and Transition 2 as equivalent intermediate states between the astrocytic/mesenchymal and proneural programmes, our analyses reveal them as distinct entities with near-disjoint fate profiles and opposing positions across all lateness orderings. This confirms, via independent methods, a separation previously implied by motif-accessibility and ligand-receptor analyses. Crucially, Transition 2 represents a transcriptionally active state adjacent to the mesenchymal-like (MES-like) phenotype, accounting for 32.3% of MES-like nearest neighbours (a 2.9-fold enrichment over background). While initial reports noted no significant post-therapy shifts in overall malignant state composition, we found that the MES-like state contracts in bevacizumab-naive patients but expands under bevacizumab exposure, with the steepest increases observed following bevacizumab combined with checkpoint inhibition (0.07 to 0.372; patient-level permutation p = 0.027 for deltas, p = 0.003 for late-stage values). Concurrently, the myeloid compartment shifts toward a bone-marrow-derived macrophage (BMDM) phenotype. We demonstrate that BMDM polarisation strongly correlates with MES-like cellular proportions across samples (ρ = +0.83). This relationship remains robust after controlling for ambient RNA contamination, cell abundance, and leave-one-patient-out analyses, and persists after adjusting for hypoxia scores calculated outside the mesenchymal compartment (partial ρ = +0.64, p = 0.0008). Restricting our analysis to seven post-treatment samples from six bevacizumab-exposed patients revealed a striking cross-compartment coupling between myeloid VEGFA and malignant AXL (r = + 0.998 overall; r = + 0.946 specifically against AXL in MES-like cells). Within the malignant compartment, expression peaks in distinct states—AXL in Transition 2 (z = + 0.189) and VEGFA in the MES-like state (z = + 0.702). This intercellular interaction is arm-specific, invariant to leave-one-patient-out omission, resides at the 100th percentile of an empirical null distribution (n = 3,540 pairs), and withstands rigorous adjustment for hypoxia, cellular composition, sequencing depth, and primary technical or biological axes. This coupling is independent of canonical VEGF signalling: receptors VEGFR1, VEGFR2, and VEGFR3 are detectable in fewer than 1% to 8% of cells across both compartments, and tested candidate messengers fail to account for the axis. Neuropilins emerge as the sole abundant VEGFA-binding molecules (NRP1 expressed in 30% to 46% of cells). NRP1 is upregulated in bevacizumab-exposed tumours beyond compositional expectations and represents a cognate receptor spared by bevacizumab blockade. Finally, a malignant IL34-driven myeloid recruitment axis is evident in bevacizumab-treated tumours, though it remains perfectly collinear with concurrent checkpoint inhibition.
- Open Access
- 30 December 2024
- Published by IOP Publishing in Biofabrication
- Vol. 17 (1) , 015040
An immunocompetent human kidney on-a-chip model to study renal inflammation and immune-mediated injury
Kidney damage and dysfunction is an emerging health issue worldwide resulting in high morbidity and mortality rates. Numerous renal diseases are recognized to be driven by the immune system. Despite this recognition, the development of targeted therapies has been challenging as knowledge of the underlying mechanism and complex interactions remains insufficient. Recent advancements in the field offer promising avenues for exploring the interplay between renal cells and immune cells and their role in the development of renal inflammation and diseases. This study describes the establishment of a human immunocompetent 3D in vitro co-culture model of the proximal tubule (PT) in a novel high-throughput microfluidic platform that can be used to study renal functionality and inflammatory processes. The model incorporated renal PT epithelial cell in the top compartment and human umbilical vein endothelial cells in the bottom compartment cultured under flow and in direct contact with a collagen-I extracellular matrix (ECM) gel resulting in the formation of polarized tubular structures. As an immune component, human primary monocytes of different donors were added to the lumen of the endothelium. Renal inflammation was successfully induced using complement activated serum (CAS) as evident by epithelial morphological changes, increased expression of adhesion molecules, release of pro-inflammatory cytokines, and reduced epithelial viability. Realtime migratory behavior of monocytes showed increased extravasation and migration towards the ECM and Renal compartment upon exposure to CAS with donor-to-donor differences observed. Finally, immune modulatory compounds showed efficacious inhibition of monocyte migration under inflammatory conditions in the microfluidic co-culture model. A successful co-culture model was established and can be applied to study renal functionality in health and disease but also for drug screening due to the compatibility of the platform with automation and relatively high throughput. Overall, the described PT model has high potential to fill the gap that currently exists to study renal inflammation preclinically.
- 30 December 2024
- Published by IOP Publishing in Biofabrication
- Vol. 17 (1) , 015040
Open AccessAn immunocompetent human kidney on-a-chip model to study renal inflammation and immune-mediated injury
Kidney damage and dysfunction is an emerging health issue worldwide resulting in high morbidity and mortality rates. Numerous renal diseases are recognized to be driven by the immune system. Despite this recognition, the development of targeted therapies has been challenging as knowledge of the underlying mechanism and complex interactions remains insufficient. Recent advancements in the field offer promising avenues for exploring the interplay between renal cells and immune cells and their role in the development of renal inflammation and diseases. This study describes the establishment of a human immunocompetent 3D in vitro co-culture model of the proximal tubule (PT) in a novel high-throughput microfluidic platform that can be used to study renal functionality and inflammatory processes. The model incorporated renal PT epithelial cell in the top compartment and human umbilical vein endothelial cells in the bottom compartment cultured under flow and in direct contact with a collagen-I extracellular matrix (ECM) gel resulting in the formation of polarized tubular structures. As an immune component, human primary monocytes of different donors were added to the lumen of the endothelium. Renal inflammation was successfully induced using complement activated serum (CAS) as evident by epithelial morphological changes, increased expression of adhesion molecules, release of pro-inflammatory cytokines, and reduced epithelial viability. Realtime migratory behavior of monocytes showed increased extravasation and migration towards the ECM and Renal compartment upon exposure to CAS with donor-to-donor differences observed. Finally, immune modulatory compounds showed efficacious inhibition of monocyte migration under inflammatory conditions in the microfluidic co-culture model. A successful co-culture model was established and can be applied to study renal functionality in health and disease but also for drug screening due to the compatibility of the platform with automation and relatively high throughput. Overall, the described PT model has high potential to fill the gap that currently exists to study renal inflammation preclinically.
- Open Access
- 12 December 2024
- Published by Frontiers Media SA in Frontiers in Systems Biology
- Vol. 4, 1466368
Immune disease dialogue of chemokine-based cell communications as revealed by single-cell RNA sequencing meta-analysis
Immune-mediated diseases are characterized by aberrant immune responses, posing significant challenges to global health. In both inflammatory and autoimmune diseases, dysregulated immune reactions mediated by tissue-residing immune and non-immune cells precipitate chronic inflammation and tissue damage that is amplified by peripheral immune cell extravasation into the tissue. Chemokine receptors are pivotal in orchestrating immune cell migration, yet deciphering the signaling code across cell types, diseases and tissues remains an open challenge. To delineate disease-specific cell-cell communications involved in immune cell migration, we conducted a meta-analysis of publicly available single-cell RNA sequencing (scRNA-seq) data across diverse immune diseases and tissues. Our comprehensive analysis spanned multiple immune disorders affecting major organs: atopic dermatitis and psoriasis (skin), chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis (lung), ulcerative colitis (colon), IgA nephropathy and lupus nephritis (kidney). By interrogating ligand-receptor (L-R) interactions, alterations in cell proportions, and differential gene expression, we unveiled disease-specific and common cell-cell communications involved in chemotaxis and extravasation to shed light on shared immune responses across tissues and diseases. Further, we performed experimental validation of two understudied cell-cell communications. Insights gleaned from this meta-analysis hold promise for the development of targeted therapeutics aimed at modulating immune cell migration to mitigate inflammation and tissue damage. This nuanced understanding of immune cell dynamics at the single-cell resolution opens avenues for precision medicine in immune disease management.
- 12 December 2024
- Published by Frontiers Media SA in Frontiers in Systems Biology
- Vol. 4, 1466368
Open AccessImmune disease dialogue of chemokine-based cell communications as revealed by single-cell RNA sequencing meta-analysis
Immune-mediated diseases are characterized by aberrant immune responses, posing significant challenges to global health. In both inflammatory and autoimmune diseases, dysregulated immune reactions mediated by tissue-residing immune and non-immune cells precipitate chronic inflammation and tissue damage that is amplified by peripheral immune cell extravasation into the tissue. Chemokine receptors are pivotal in orchestrating immune cell migration, yet deciphering the signaling code across cell types, diseases and tissues remains an open challenge. To delineate disease-specific cell-cell communications involved in immune cell migration, we conducted a meta-analysis of publicly available single-cell RNA sequencing (scRNA-seq) data across diverse immune diseases and tissues. Our comprehensive analysis spanned multiple immune disorders affecting major organs: atopic dermatitis and psoriasis (skin), chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis (lung), ulcerative colitis (colon), IgA nephropathy and lupus nephritis (kidney). By interrogating ligand-receptor (L-R) interactions, alterations in cell proportions, and differential gene expression, we unveiled disease-specific and common cell-cell communications involved in chemotaxis and extravasation to shed light on shared immune responses across tissues and diseases. Further, we performed experimental validation of two understudied cell-cell communications. Insights gleaned from this meta-analysis hold promise for the development of targeted therapeutics aimed at modulating immune cell migration to mitigate inflammation and tissue damage. This nuanced understanding of immune cell dynamics at the single-cell resolution opens avenues for precision medicine in immune disease management.
- Open Access
Immune disease dialogue of chemokine-based cell communications as revealed by single-cell RNA sequencing meta-analysis
Immune-mediated diseases are characterized by aberrant immune responses, posing significant challenges to global health. In both inflammatory and autoimmune diseases, dysregulated immune reactions mediated by tissue-residing immune and non-immune cells precipitate chronic inflammation and tissue damage that is amplified by peripheral immune cell extravasation into the tissue. Chemokine receptors are pivotal in orchestrating immune cell migration, yet deciphering the signaling code across cell types, diseases and tissues remains an open challenge. To delineate disease-specific cell-cell communications involved in immune cell migration, we conducted a meta-analysis of publicly available single-cell RNA sequencing (scRNA-seq) data across diverse immune diseases and tissues. Our comprehensive analysis spanned multiple immune disorders affecting major organs: atopic dermatitis and psoriasis (skin), chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis (lung), ulcerative colitis (colon), IgA nephropathy and lupus nephritis (kidney). By interrogating ligand-receptor (L-R) interactions, alterations in cell proportions, and differential gene expression, we unveiled intricate disease- specific and common immune cell chemoattraction and extravasation patterns. Our findings delineate disease-specific L-R networks and shed light on shared immune responses across tissues and diseases. Insights gleaned from this analysis hold promise for the development of targeted therapeutics aimed at modulating immune cell migration to mitigate inflammation and tissue damage. This nuanced understanding of immune cell dynamics at the single-cell resolution opens avenues for precision medicine in immune disease management.
Open AccessImmune disease dialogue of chemokine-based cell communications as revealed by single-cell RNA sequencing meta-analysis
Immune-mediated diseases are characterized by aberrant immune responses, posing significant challenges to global health. In both inflammatory and autoimmune diseases, dysregulated immune reactions mediated by tissue-residing immune and non-immune cells precipitate chronic inflammation and tissue damage that is amplified by peripheral immune cell extravasation into the tissue. Chemokine receptors are pivotal in orchestrating immune cell migration, yet deciphering the signaling code across cell types, diseases and tissues remains an open challenge. To delineate disease-specific cell-cell communications involved in immune cell migration, we conducted a meta-analysis of publicly available single-cell RNA sequencing (scRNA-seq) data across diverse immune diseases and tissues. Our comprehensive analysis spanned multiple immune disorders affecting major organs: atopic dermatitis and psoriasis (skin), chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis (lung), ulcerative colitis (colon), IgA nephropathy and lupus nephritis (kidney). By interrogating ligand-receptor (L-R) interactions, alterations in cell proportions, and differential gene expression, we unveiled intricate disease- specific and common immune cell chemoattraction and extravasation patterns. Our findings delineate disease-specific L-R networks and shed light on shared immune responses across tissues and diseases. Insights gleaned from this analysis hold promise for the development of targeted therapeutics aimed at modulating immune cell migration to mitigate inflammation and tissue damage. This nuanced understanding of immune cell dynamics at the single-cell resolution opens avenues for precision medicine in immune disease management.
- Open Access
- 13 June 2024
- Published by Elsevier in Cell Reports Methods
- Vol. 4 (6) , 100794
GENIX enables comparative network analysis of single-cell RNA sequencing to reveal signatures of therapeutic interventions
- 13 June 2024
- Published by Elsevier in Cell Reports Methods
- Vol. 4 (6) , 100794
Open AccessGENIX enables comparative network analysis of single-cell RNA sequencing to reveal signatures of therapeutic interventions
- Open Access
An immunocompetent human kidney on-a-chip model to study renal inflammation and immune-mediated injury
Kidney damage and dysfunction is an emerging health issue worldwide resulting in high morbidity and mortality rates. Numerous renal diseases are recognized to be driven by the immune system. Despite this recognition, the development of targeted therapies has been challenging as knowledge of the underlying mechanism and complex interactions remains insufficient. Recent advancements in the field offer promising avenues for exploring the interplay between renal cells and immune cells and their role in the development of renal inflammation and diseases. This study describes the establishment of a human immunocompetent 3D in vitro co-culture model of the proximal tubule in a high-throughput microfluidic platform that can be used to study renal functionality and inflammatory processes. The model incorporated RPTEC in the top compartment and HUVECs in the bottom compartment cultured under flow and in direct contact with a collagen-I ECM gel resulting in the formation of polarized tubular structures. As an immune component, human primary monocytes of different donors were added to the lumen of the endothelium. Renal inflammation was successfully induced using complement activated serum (CAS) as evident by epithelial morphological changes, increased expression of adhesion molecules, release of pro-inflammatory cytokines, and reduced epithelial viability. Realtime migratory behavior of monocytes showed increased extravasation and migration towards the ECM and Renal compartment upon exposure to CAS with donor-to-donor differences observed. Finally, immune modulatory compounds showed efficacious inhibition of monocyte migration under inflammatory conditions in the microfluidic co-culture model. A successful co-culture model was established and can be applied to study renal functionality in health and disease but also for drug screening due to the compatibility of the platform with automation and relatively high throughput. Overall, the described proximal tubule model has high potential to fill the gap that currently exists to study renal inflammation preclinically.
Open AccessAn immunocompetent human kidney on-a-chip model to study renal inflammation and immune-mediated injury
Kidney damage and dysfunction is an emerging health issue worldwide resulting in high morbidity and mortality rates. Numerous renal diseases are recognized to be driven by the immune system. Despite this recognition, the development of targeted therapies has been challenging as knowledge of the underlying mechanism and complex interactions remains insufficient. Recent advancements in the field offer promising avenues for exploring the interplay between renal cells and immune cells and their role in the development of renal inflammation and diseases. This study describes the establishment of a human immunocompetent 3D in vitro co-culture model of the proximal tubule in a high-throughput microfluidic platform that can be used to study renal functionality and inflammatory processes. The model incorporated RPTEC in the top compartment and HUVECs in the bottom compartment cultured under flow and in direct contact with a collagen-I ECM gel resulting in the formation of polarized tubular structures. As an immune component, human primary monocytes of different donors were added to the lumen of the endothelium. Renal inflammation was successfully induced using complement activated serum (CAS) as evident by epithelial morphological changes, increased expression of adhesion molecules, release of pro-inflammatory cytokines, and reduced epithelial viability. Realtime migratory behavior of monocytes showed increased extravasation and migration towards the ECM and Renal compartment upon exposure to CAS with donor-to-donor differences observed. Finally, immune modulatory compounds showed efficacious inhibition of monocyte migration under inflammatory conditions in the microfluidic co-culture model. A successful co-culture model was established and can be applied to study renal functionality in health and disease but also for drug screening due to the compatibility of the platform with automation and relatively high throughput. Overall, the described proximal tubule model has high potential to fill the gap that currently exists to study renal inflammation preclinically.
- Open Access
Estimating the impact of single-cell RNA sequencing of human tissues on drug target validation
Whilst the use of single-cell RNA sequencing (scRNA-seq) to understand target biology is well established, its predictive role in increasing the clinical success of therapeutic targets remains underexplored. Inspired by previous work on an association between genetic evidence and clinical success, we used retrospective analysis of known drug target genes to identify potential predictors of target clinical success from scRNA-seq data. We investigated whether successful drug targets are associated with cell type specific expression in a disease-relevant tissue (cell type specificity), and with cell type specific over-expression in disease patients compared to healthy controls (disease cell specificity). Analysing scRNA-seq data across diseases and tissues, we found that both cell type and disease cell specificity are features enriched in targets entering clinical development, and that cell type specificity in the disease-relevant tissue is robustly predictive of target progression from Phase I to II. While scRNA-seq analysis identifies a larger and complementary target space to that of direct genetic evidence, its association with specificity and drug approval appears less clear. We discuss how further expansion and harmonization of single-cell datasets, more sophisticated integration of this data in target discovery, and improved methods for tracking clinical trial outcomes could enhance our ability to leverage scRNA-seq insights in drug development in future.
Open AccessEstimating the impact of single-cell RNA sequencing of human tissues on drug target validation
Whilst the use of single-cell RNA sequencing (scRNA-seq) to understand target biology is well established, its predictive role in increasing the clinical success of therapeutic targets remains underexplored. Inspired by previous work on an association between genetic evidence and clinical success, we used retrospective analysis of known drug target genes to identify potential predictors of target clinical success from scRNA-seq data. We investigated whether successful drug targets are associated with cell type specific expression in a disease-relevant tissue (cell type specificity), and with cell type specific over-expression in disease patients compared to healthy controls (disease cell specificity). Analysing scRNA-seq data across diseases and tissues, we found that both cell type and disease cell specificity are features enriched in targets entering clinical development, and that cell type specificity in the disease-relevant tissue is robustly predictive of target progression from Phase I to II. While scRNA-seq analysis identifies a larger and complementary target space to that of direct genetic evidence, its association with specificity and drug approval appears less clear. We discuss how further expansion and harmonization of single-cell datasets, more sophisticated integration of this data in target discovery, and improved methods for tracking clinical trial outcomes could enhance our ability to leverage scRNA-seq insights in drug development in future.
- Open Access
- 1 December 2023
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 39 (12)
Scaling up single-cell RNA-seq data analysis with CellBridge workflow
Summary: Single-cell RNA sequencing (scRNA-seq) has revolutionized the study of gene expression at the individual cell level, unraveling unprecedented insights into cellular heterogeneity. However, the analysis of scRNA-seq data remains a challenging and time-consuming task, often demanding advanced computational expertise, rendering it impractical for high-volume environments and applications. We present CellBridge, an automated workflow designed to simplify the standard procedures entailed in scRNA-seq data analysis, eliminating the need for specialized computational expertise. CellBridge utilizes state-of-the-art computational methods, integrating a range of advanced functionalities, covering the entire process from raw unaligned sequencing reads to cell type annotation. Hence, CellBridge accelerates the pace of discovery by seamlessly enabling insights into vast volumes of scRNA-seq data, without compromising workflow control and reproducibility. Availability and implementation: The source code, detailed documentation, and materials required to reproduce the results are available on GitHub and archived in Zenodo. For the CellBridge pre-processing step (v1.0.0), access the GitHub repository at https://github.com/Sanofi-Public/PMCB-ToBridge and the Zenodo archive at https://zenodo.org/records/10246161. For the CellBridge processing step (v1.0.0), visit the GitHub repository at https://github.com/Sanofi-Public/PMCB-CellBridge and the Zenodo archive at https://zenodo.org/records/10246046.
- 1 December 2023
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 39 (12)
Open AccessScaling up single-cell RNA-seq data analysis with CellBridge workflow
Summary: Single-cell RNA sequencing (scRNA-seq) has revolutionized the study of gene expression at the individual cell level, unraveling unprecedented insights into cellular heterogeneity. However, the analysis of scRNA-seq data remains a challenging and time-consuming task, often demanding advanced computational expertise, rendering it impractical for high-volume environments and applications. We present CellBridge, an automated workflow designed to simplify the standard procedures entailed in scRNA-seq data analysis, eliminating the need for specialized computational expertise. CellBridge utilizes state-of-the-art computational methods, integrating a range of advanced functionalities, covering the entire process from raw unaligned sequencing reads to cell type annotation. Hence, CellBridge accelerates the pace of discovery by seamlessly enabling insights into vast volumes of scRNA-seq data, without compromising workflow control and reproducibility. Availability and implementation: The source code, detailed documentation, and materials required to reproduce the results are available on GitHub and archived in Zenodo. For the CellBridge pre-processing step (v1.0.0), access the GitHub repository at https://github.com/Sanofi-Public/PMCB-ToBridge and the Zenodo archive at https://zenodo.org/records/10246161. For the CellBridge processing step (v1.0.0), visit the GitHub repository at https://github.com/Sanofi-Public/PMCB-CellBridge and the Zenodo archive at https://zenodo.org/records/10246046.
- Open Access
Comparative Analysis of Association Networks Using Single-Cell RNA Sequencing Data Reveals Perturbation-Relevant Gene Signatures
Single-cell RNA sequencing (scRNA-seq) data has elevated our understanding of systemic perturbations to organismal physiology at the individual cell level. However, despite the rich information content of scRNA-seq data, the relevance of genes to a perturbation is still commonly assessed through differential expression analysis. This approach provides a one-dimensional perspective of the transcriptomic landscape, risking the oversight of tightly controlled genes characterized by modest changes in expression but with profound downstream effects. We present GENIX (Gene Expression Network Importance eXamination), a novel platform for constructing gene association networks, equipped with an innovative network-based comparative model to uncover condition-relevant genes. To demonstrate the effectiveness of GENIX, we analyze influenza vaccine-induced immune responses in peripheral blood mononuclear cells (PBMCs) collected from recovered COVID-19 patients, shedding light on the mechanistic underpinnings of gender differences. Our methodology offers a promising avenue to identify genes relevant to perturbation responses in biological systems, expanding the scope of response signature discovery beyond differential gene expression analysis. HIGHLIGHTS Conventional methods used to identify perturbation-relevant genes in scRNA-seq data rely on differential expression analysis, susceptible to overlooking essential genes. GENIX leverages cell-type-specific inferred gene association networks to identify condition-relevant genes and gene programs, irrespective of their specific expression alterations. GENIX provides insight into the gene-regulatory response to the influenza vaccine in naïve and recovered COVID-19 patients, expanding on previously observed gender-specific differences.
Open AccessComparative Analysis of Association Networks Using Single-Cell RNA Sequencing Data Reveals Perturbation-Relevant Gene Signatures
Single-cell RNA sequencing (scRNA-seq) data has elevated our understanding of systemic perturbations to organismal physiology at the individual cell level. However, despite the rich information content of scRNA-seq data, the relevance of genes to a perturbation is still commonly assessed through differential expression analysis. This approach provides a one-dimensional perspective of the transcriptomic landscape, risking the oversight of tightly controlled genes characterized by modest changes in expression but with profound downstream effects. We present GENIX (Gene Expression Network Importance eXamination), a novel platform for constructing gene association networks, equipped with an innovative network-based comparative model to uncover condition-relevant genes. To demonstrate the effectiveness of GENIX, we analyze influenza vaccine-induced immune responses in peripheral blood mononuclear cells (PBMCs) collected from recovered COVID-19 patients, shedding light on the mechanistic underpinnings of gender differences. Our methodology offers a promising avenue to identify genes relevant to perturbation responses in biological systems, expanding the scope of response signature discovery beyond differential gene expression analysis. HIGHLIGHTS Conventional methods used to identify perturbation-relevant genes in scRNA-seq data rely on differential expression analysis, susceptible to overlooking essential genes. GENIX leverages cell-type-specific inferred gene association networks to identify condition-relevant genes and gene programs, irrespective of their specific expression alterations. GENIX provides insight into the gene-regulatory response to the influenza vaccine in naïve and recovered COVID-19 patients, expanding on previously observed gender-specific differences.
- Open Access
A marker gene-based method for identifying the cell-type of origin from single-cell RNA sequencing data